Form 8-K - Current report:
SEC Accession No. 0001193125-25-039256
Filing Date
2025-02-27
Accepted
2025-02-27 16:15:54
Documents
13
Period of Report
2025-02-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d928060d8k.htm   iXBRL 8-K 22419
  Complete submission text file 0001193125-25-039256.txt   140062

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20250222.xsd EX-101.SCH 2868
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20250222_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20250222_pre.xml EX-101.PRE 10824
15 EXTRACTED XBRL INSTANCE DOCUMENT d928060d8k_htm.xml XML 3507
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 25679015
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)